首都医科大学学报 ›› 2026, Vol. 47 ›› Issue (3): 449-456.doi: 10.3969/j.issn.1006-7795.2026.03.006

• 从分子机制到临床应用:创新药物新突破 • 上一篇    下一篇

临时调配口服溶剂介质混合药物体系的质量属性研究

塔娜1,2,3,杨梅1,于锋3,黄旻4,王晓玲1,2,梅冬1,2*   

  1. 1.国家儿童医学中心  首都医科大学附属北京儿童医院药学部, 北京 100045; 2.首都医科大学基础-临床联合实验室(儿童肿瘤发病机制与创新药物研究实验室),北京  100069; 3 中国药科大学基础医学与临床药学学院, 南京 211198; 4.浙江贝灵生物医药有限公司, 杭州 310051
  • 收稿日期:2026-02-13 修回日期:2026-03-16 出版日期:2026-06-21 发布日期:2026-06-26
  • 通讯作者: 梅冬 E-mail:meidong11290926@126.com
  • 基金资助:
    国家重点研发计划项目(2023YFC2706100)。

Quality attribute evaluation of drug-vehicle systems in extemporaneous compounding oral pharmaceutical vehicles

Ta Na1,2,3, Yang Mei1, Yu Feng3, Huang Min4,  Wang Xiaoling1,2, Mei Dong1,2*   

  1. 1.Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China; 2.Laboratory for Clinical Medicine (Laboratory of Pediatric Tumor Pathogenesis and Innovative Drug Research), Capital Medical University, Beijing 100069, China; 3.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; 4.Zhejiang Beiling Biological Medicine Company Limited, Hangzhou 310051, China
  • Received:2026-02-13 Revised:2026-03-16 Online:2026-06-21 Published:2026-06-26
  • Supported by:
    This study was supported by National Key Research and Development Program of China (2023YFC2706100).

摘要: 目的  评价临时调配口服溶剂介质在儿童及特殊人群分剂量给药中的应用可行性,考察不同生物药剂学分类系统(Biopharmaceutics Classification System,BCS)分类药物在该体系中的含量均匀度与稳定性,为临床合理用药提供依据。方法  选取氟康唑(BCS Ⅰ类)、双嘧达莫(BCS Ⅱ类)、盐酸普萘洛尔(BCS Ⅲ类)和呋塞米(BCS Ⅳ类)4 种代表性药物,采用临床常规研磨流程处理后加入口服溶剂介质中进行临时调配,考察混悬液中不同位置取样点的含量均匀度,以及在5 ℃和25 ℃储存条件下不同时间点的含量变化,并进行统计学分析。结果  4种药物在口服溶剂介质中的含量和均匀度均符合《中国药典》限度要求[相对标准偏差 (relative standard deviation,RSD)<15%],不同 BCS 分类药物的 RSD 存在差异。稳定性考察结果显示,各药物在所考察储存条件下,在30~90 d 内含量变化幅度较小。结论  该口服溶剂介质可支持不同理化性质药物的临时调配,在分剂量给药应用场景下表现出良好的含量均匀度与稳定性,这有望为儿童及特殊人群分剂量用药提供一种可行的技术方案。

关键词: 临时调配, 口服溶剂介质, 分剂量给药, 生物药剂学分类系统, 个性化给药, 特殊人群

Abstract: Objective  To evaluate the feasibility of an extemporaneous compounding oral pharmaceutical vehicle for dose-splitting administration in children and special populations, and to investigate the content uniformity and stability of drugs with different Biopharmaceutics Classification System (BCS) classes in this system. Methods  Four representative drugs were selected, including fluconazole (BCS class Ⅰ), dipyridamole (BCS class Ⅱ), propranolol hydrochloride (BCS class Ⅲ), and furosemide (BCS class Ⅳ). After processing with a routine clinical grinding procedure, the drugs were added to the oral pharmaceutical vehicle for extemporaneous compounding. The content uniformity at different spatial sampling positions of the suspension and the content changes at different time points under 5 ℃ and 25 ℃ storage conditions were evaluated and followed by statistical analysis. Results  The content uniformity of all four drugs in the oral pharmaceutical vehicle met the acceptance criteria of the Chinese Pharmacopoeia [relative standard deviation (RSD) < 15%]. Differences in RSD values were observed among drugs of different BCS classes. Stability studies showed that drug contents exhibited only minor changes during the evaluated storage periods of 30-90. Conclusion  The oral pharmaceutical vehicle can support the extemporaneous compounding of drugs with different physicochemical properties and demonstrates acceptable content uniformity and stability in dose-splitting administration scenarios, indicating its potential as a feasible technical option for medication use in children and special populations.

Key words: extemporaneous compounding, oral pharmaceutical vehicle, dose-splitting administration, Biopharmaceutics Classification System, personalized medication, vulnerable populations

中图分类号: